Anas G.
- Country
- France
- Department
- Drug Development Department (DITEP)
Research Overview
- Safety and Efficacy Evaluation of RO7759065 with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
- Evaluation of MAQ-001 Monotherapy and Combination Therapy in Advanced Cancers with Approved Immune Checkpoint Blockade Options
- Phase 1 Evaluation of BL-B01D1 Safety, Tolerability, and Efficacy in Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors
Data & Insights
Has run more than one trial at 82 of 146 partner sites.
Specializations
Lung Cancer Specialization
This investigator demonstrates significant expertise in treating various forms of lung cancer, particularly focusing on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Their research encompasses both advanced and metastatic stages of these conditions.
- Advanced Non-Squamous NSCLC
- Extensive Stage Small Cell Lung Cancer
- MET-altered Lung Tumors
Advanced Solid Tumors
The investigator works extensively with locally advanced and metastatic solid tumors, investigating novel therapeutic approaches. Their work includes research on tumors with specific genetic markers and molecular characteristics.
- MAPK Pathway Mutant Tumors
- Advanced Solid Malignancies
- Metastatic Disease Management
Innovative Cancer Therapies
The investigator explores immunotherapy approaches and novel therapeutic combinations, including research with monoclonal antibodies and targeted treatments.
- Antibody-Drug Conjugates
- PD-1 Blocking Treatments
- Combination Therapy Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.